Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,059.37

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,031.59 57
Education $27.78 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $1,059.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amneal Pharmaceuticals LLC $13.4812/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667317 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4212/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716532 CMS
Smith+Nephew, Inc. $59.5812/09/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 843159417 CMS
Eisai Inc. $18.5912/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845775529 CMS
AstraZeneca Pharmaceuticals LP $15.0211/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829654089 CMS
AstraZeneca Pharmaceuticals LP $16.3311/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829776629 CMS
Novo Nordisk Inc $24.1711/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094405 CMS
Endo Pharmaceuticals Inc. $16.3210/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828700153 CMS
AstraZeneca Pharmaceuticals LP $13.3710/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829548257 CMS
Merck Sharp & Dohme Corporation $12.9610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848445245 CMS
Genentech USA, Inc. $14.9910/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835942209 CMS
Abbott Laboratories $18.4510/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815725597 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.0110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789035181 CMS
AstraZeneca Pharmaceuticals LP $14.0409/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829351817 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.7809/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716534 CMS
Amgen Inc. $13.8909/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534999 CMS
Amneal Pharmaceuticals LLC $11.6709/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667311 CMS
DEXCOM, INC. $16.9209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286859 CMS
Novo Nordisk Inc $19.5209/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811133699 CMS
Abbott Laboratories $22.4608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732605 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.2408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789167369 CMS
Lilly USA, LLC $22.4708/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818660655 CMS
Merck Sharp & Dohme Corporation $14.8308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848467299 CMS
Amgen Inc. $18.2708/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560071 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.6607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716536 CMS
AstraZeneca Pharmaceuticals LP $13.6007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829901891 CMS
Novo Nordisk Inc $16.4507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810976691 CMS
Novo Nordisk Inc $2.5206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897871 CMS
Novo Nordisk Inc $19.1306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897879 CMS
AstraZeneca Pharmaceuticals LP $14.6006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829897633 CMS
AstraZeneca Pharmaceuticals LP $12.1806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829938303 CMS
SANOFI-AVENTIS U.S. LLC $20.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408675 CMS
AstraZeneca Pharmaceuticals LP $13.9506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829329589 CMS
AstraZeneca Pharmaceuticals LP $12.4006/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829395613 CMS
Amgen Inc. $14.8506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560067 CMS
DEXCOM, INC. $18.4205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286857 CMS
Novo Nordisk Inc $24.1105/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810937589 CMS
Lilly USA, LLC $11.5505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818596861 CMS
Merck Sharp & Dohme Corporation $11.2004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848597345 CMS
Amneal Pharmaceuticals LLC $18.7804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667307 CMS
AstraZeneca Pharmaceuticals LP $16.5204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830073867 CMS
Novo Nordisk Inc $17.5704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094399 CMS
SANOFI-AVENTIS U.S. LLC $20.9804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408643 CMS
Amgen Inc. $13.5004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560063 CMS
Amgen Inc. $13.8904/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534997 CMS
Novo Nordisk Inc $20.2203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811173081 CMS
SANOFI-AVENTIS U.S. LLC $16.8603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408607 CMS
Radius Health, Inc. $23.2803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830727017 CMS
AstraZeneca Pharmaceuticals LP $13.1802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829485817 CMS
AstraZeneca Pharmaceuticals LP $13.6802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829984441 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,000.00 12/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202531174
Principal investigator 1 Verona Pharma, Inc. $1,000.00 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892607
Principal investigator 1 Verona Pharma, Inc. $2,500.00 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892609
Principal investigator 1 Verona Pharma, Inc. $128,245.20 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,237.50 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,622.50 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,000.00 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,485.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,579.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,305.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $756.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269193
Principal investigator 1 Verona Pharma, Inc. $1,693.27 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892751
Principal investigator 1 Verona Pharma, Inc. $5,000.00 11/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892621
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,194.70 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185542308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,369.75 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261323
Principal investigator 1 Verona Pharma, Inc. $5,000.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892625
Principal investigator 1 Verona Pharma, Inc. $203,818.64 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,295.80 11/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258957
Principal investigator 1 Verona Pharma, Inc. $18,319.65 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892785
Principal investigator 1 ABBVIE INC. $2,227.50 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202520885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,357.85 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,434.47 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252610
Principal investigator 1 Verona Pharma, Inc. $3,257.20 10/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,526.08 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $661.50 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $425.25 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,592.50 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $810.00 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,175.00 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,160.50 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250663
Principal investigator 1 ABBVIE INC. $1,880.45 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202515735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,642.34 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248954
Principal investigator 1 Verona Pharma, Inc. $13,500.00 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892605
Principal investigator 1 Verona Pharma, Inc. $2,500.00 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,071.57 10/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244639
Principal investigator 1 Verona Pharma, Inc. $10,000.00 09/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892741
Principal investigator 1 Verona Pharma, Inc. $2,500.00 09/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,469.00 09/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,655.83 09/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 09/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $271,923.44 09/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,463.81 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184234999
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226143927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $571.05 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,456.68 08/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229739
Principal investigator 1 ABBVIE INC. $7,341.75 08/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502895
Principal investigator 1 ABBVIE INC. $1,542.45 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202501608
Principal investigator 1 ABBVIE INC. $613.25 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202501610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,987.50 07/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222828
Principal investigator 1 ABBVIE INC. $9,107.45 07/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202500304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.53 07/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,332.50 07/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $579.74 07/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217757
Principal investigator 1 SANOFI US SERVICES INC. $3,300.00 07/21/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226143908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,200.21 07/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217064
Principal investigator 1 UCB SA $3,700.00 07/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,435.00 07/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214362
Principal investigator 1 SANOFI US SERVICES INC. $453.00 07/07/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226143903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,214.46 07/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,950.00 07/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,015.35 07/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.75 07/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212845
Principal investigator 1 ABBVIE INC. $870.00 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202494617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,730.06 06/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209165
Principal investigator 1 ABBVIE INC. $4,260.00 06/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202491357
Principal investigator 1 Verona Pharma, Inc. $1,725.83 06/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,363.18 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,928.16 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,464.08 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,329.11 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,542.50 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,227.50 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204173
Principal investigator 1 ABBVIE INC. $1,485.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,857.11 05/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197591
Principal investigator 1 Eli Lilly and Company $575.00 05/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187879477
Principal investigator 1 ABBVIE INC. $742.50 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482951
Principal investigator 1 ABBVIE INC. $1,542.45 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202481633
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 05/05/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226143878
Principal investigator 1 ABBVIE INC. $1,801.60 04/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202479823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,460.12 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,093.24 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,456.42 04/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183418
Principal investigator 1 SANOFI US SERVICES INC. $180.00 04/14/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226143873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,928.95 04/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,935.92 04/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,981.50 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $243.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,161.25 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,847.50 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,197.50 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180820
Principal investigator 1 Verona Pharma, Inc. $448.88 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892699
Principal investigator 1 Verona Pharma, Inc. $4,000.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892705
Principal investigator 1 Verona Pharma, Inc. $4,565.70 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892665
Principal investigator 1 Verona Pharma, Inc. $7,812.71 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892679
Principal investigator 1 Verona Pharma, Inc. $5,000.00 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892683
Principal investigator 1 SANOFI US SERVICES INC. $7,500.00 03/10/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226143855
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 03/10/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226143861
Principal investigator 1 ABBVIE INC. $6,889.50 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460237
Principal investigator 1 ABBVIE INC. $1,633.75 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202457340
Principal investigator 1 Verona Pharma, Inc. $4,991.25 03/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,683.54 03/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156746
Principal investigator 1 Verona Pharma, Inc. $4,806.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892663
Principal investigator 1 Verona Pharma, Inc. $750.00 02/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892677
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,582.10 02/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1185542302
Principal investigator 1 Eli Lilly and Company $751.65 02/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187877905
Principal investigator 1 ABBVIE INC. $1,542.45 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202445117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.79 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152456
Principal investigator 1 Eli Lilly and Company $640.30 01/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187878435
Principal investigator 1 AstraZeneca Pharmaceuticals LP $83,888.00 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185542304
Principal investigator 1 AstraZeneca Pharmaceuticals LP $385,024.25 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185542306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,739.83 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149884
Principal investigator 1 Eli Lilly and Company $15,800.00 01/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187877901
Principal investigator 1 Eli Lilly and Company $9,114.75 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187879483
Principal investigator 1 Eli Lilly and Company $669.02 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187883094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,533.28 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148111
Principal investigator 1 Verona Pharma, Inc. $52,246.23 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892659
Principal investigator 1 Verona Pharma, Inc. $8,263.67 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892661
Principal investigator 1 Eli Lilly and Company $310,728.00 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187879137
Principal investigator 1 Eli Lilly and Company $82,253.00 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187879747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,563.39 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145800
Principal investigator 1 AstraZeneca Pharmaceuticals LP $73,876.68 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185542300
Principal investigator 1 ABBVIE INC. $981.25 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433768
Principal investigator 1 ABBVIE INC. $323.25 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202434930
Principal investigator 1 Novartis Pharmaceuticals Corporation $489,796.76 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301527